Does the media refer more to COGT or RARE?

In the previous week, Ultragenyx Pharmaceutical had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 5 mentions for Ultragenyx Pharmaceutical and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.18 beat Ultragenyx Pharmaceutical's score of 0.13 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to DNTH or RARE?

In the previous week, Dianthus Therapeutics had 3 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 8 mentions for Dianthus Therapeutics and 5 mentions for Ultragenyx Pharmaceutical. Dianthus Therapeutics' average media sentiment score of 0.86 beat Ultragenyx Pharmaceutical's score of 0.13 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to PTCT or RARE?

In the previous week, PTC Therapeutics had 4 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 9 mentions for PTC Therapeutics and 5 mentions for Ultragenyx Pharmaceutical. PTC Therapeutics' average media sentiment score of 1.13 beat Ultragenyx Pharmaceutical's score of 0.13 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to RARE or XENE?

In the previous week, Xenon Pharmaceuticals had 4 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 9 mentions for Xenon Pharmaceuticals and 5 mentions for Ultragenyx Pharmaceutical. Xenon Pharmaceuticals' average media sentiment score of 0.82 beat Ultragenyx Pharmaceutical's score of 0.13 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Xenon Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to RARE or LGND?

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 8 mentions for Ligand Pharmaceuticals and 5 mentions for Ultragenyx Pharmaceutical. Ligand Pharmaceuticals' average media sentiment score of 1.37 beat Ultragenyx Pharmaceutical's score of 0.13 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ligand Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ultragenyx Pharmaceutical (RARE) Competitors

$13.78 -0.52 (-3.64%)

As of 03:36 PM Eastern

Compare

RARE vs. COGT, DNTH, PTCT, XENE, and LGND

Should you buy Ultragenyx Pharmaceutical stock or one of its competitors? Ultragenyx Pharmaceutical's main competitors and comparable companies include Cogent Biosciences (COGT), Dianthus Therapeutics (DNTH), PTC Therapeutics (PTCT), Xenon Pharmaceuticals (XENE), and Ligand Pharmaceuticals (LGND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ultragenyx Pharmaceutical compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Cogent Biosciences has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Cogent Biosciences has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Cogent Biosciences' return on equity of -84.47% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

In the previous week, Ultragenyx Pharmaceutical had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 5 mentions for Ultragenyx Pharmaceutical and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.18 beat Ultragenyx Pharmaceutical's score of 0.13 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cogent Biosciences has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Cogent Biosciences is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Ultragenyx Pharmaceutical	$717M	1.89	-$575M	-$5.84	N/A

Cogent Biosciences currently has a consensus price target of $51.56, indicating a potential upside of 54.73%. Ultragenyx Pharmaceutical has a consensus price target of $36.63, indicating a potential upside of 165.83%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Ultragenyx Pharmaceutical	1 Sell rating(s)	9 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.52

Summary

Cogent Biosciences and Ultragenyx Pharmaceutical tied by winning 7 of the 14 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Dianthus Therapeutics presently has a consensus price target of $129.83, suggesting a potential upside of 20.91%. Ultragenyx Pharmaceutical has a consensus price target of $36.63, suggesting a potential upside of 165.83%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Ultragenyx Pharmaceutical	1 Sell rating(s)	9 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.52

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dianthus Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,877.68	-$162.34M	-$4.15	N/A
Ultragenyx Pharmaceutical	$717M	1.89	-$575M	-$5.84	N/A

Dianthus Therapeutics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

In the previous week, Dianthus Therapeutics had 3 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 8 mentions for Dianthus Therapeutics and 5 mentions for Ultragenyx Pharmaceutical. Dianthus Therapeutics' average media sentiment score of 0.86 beat Ultragenyx Pharmaceutical's score of 0.13 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Ultragenyx Pharmaceutical has a net margin of -81.79% compared to Dianthus Therapeutics' net margin of -10,096.95%. Dianthus Therapeutics' return on equity of -22.53% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

Summary

Dianthus Therapeutics beats Ultragenyx Pharmaceutical on 10 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PTC Therapeutics presently has a consensus price target of $98.50, indicating a potential upside of 48.24%. Ultragenyx Pharmaceutical has a consensus price target of $36.63, indicating a potential upside of 165.83%. Given Ultragenyx Pharmaceutical's higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Ultragenyx Pharmaceutical	1 Sell rating(s)	9 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.52

In the previous week, PTC Therapeutics had 4 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 9 mentions for PTC Therapeutics and 5 mentions for Ultragenyx Pharmaceutical. PTC Therapeutics' average media sentiment score of 1.13 beat Ultragenyx Pharmaceutical's score of 0.13 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

PTC Therapeutics has higher revenue and earnings than Ultragenyx Pharmaceutical. PTC Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.20	$682.64M	-$0.58	N/A
Ultragenyx Pharmaceutical	$717M	1.89	-$575M	-$5.84	N/A

PTC Therapeutics has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

PTC Therapeutics has a net margin of -3.80% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. PTC Therapeutics' return on equity of -362.45% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%

Summary

PTC Therapeutics beats Ultragenyx Pharmaceutical on 12 of the 15 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Xenon Pharmaceuticals?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, Xenon Pharmaceuticals had 4 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 9 mentions for Xenon Pharmaceuticals and 5 mentions for Ultragenyx Pharmaceutical. Xenon Pharmaceuticals' average media sentiment score of 0.82 beat Ultragenyx Pharmaceutical's score of 0.13 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Ultragenyx Pharmaceutical currently has a consensus target price of $36.63, suggesting a potential upside of 165.83%. Xenon Pharmaceuticals has a consensus target price of $77.13, suggesting a potential upside of 32.40%. Given Ultragenyx Pharmaceutical's higher probable upside, equities research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	9 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.52
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Xenon Pharmaceuticals has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Xenon Pharmaceuticals' return on equity of -43.98% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

Xenon Pharmaceuticals has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$717M	1.89	-$575M	-$5.84	N/A
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.74	N/A

Summary

Xenon Pharmaceuticals beats Ultragenyx Pharmaceutical on 11 of the 16 factors compared between the two stocks.

How does Ultragenyx Pharmaceutical compare to Ligand Pharmaceuticals?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Ligand Pharmaceuticals has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$717M	1.89	-$575M	-$5.84	N/A
Ligand Pharmaceuticals	$268.09M	21.04	$124.45M	$9.35	30.26

Ultragenyx Pharmaceutical has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Ligand Pharmaceuticals has a net margin of 67.88% compared to Ultragenyx Pharmaceutical's net margin of -81.79%. Ligand Pharmaceuticals' return on equity of 20.06% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	-1,024.42%	-44.40%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 8 mentions for Ligand Pharmaceuticals and 5 mentions for Ultragenyx Pharmaceutical. Ligand Pharmaceuticals' average media sentiment score of 1.37 beat Ultragenyx Pharmaceutical's score of 0.13 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ultragenyx Pharmaceutical presently has a consensus price target of $36.63, indicating a potential upside of 165.83%. Ligand Pharmaceuticals has a consensus price target of $335.75, indicating a potential upside of 18.67%. Given Ultragenyx Pharmaceutical's higher possible upside, research analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	9 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.52
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Ligand Pharmaceuticals beats Ultragenyx Pharmaceutical on 12 of the 17 factors compared between the two stocks.

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RARE vs. The Competition

Export

Metric	Ultragenyx Pharmaceutical	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.36B	$3.88B	$7.21B	$13.04B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-2.36	14.74	274.15	25.47
Price / Sales	1.89	1,421.51	639.31	88.17
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	-16.60	15.30	10.43	6.26
Net Income	-$575M	-$22.82M	$3.49B	$358.19M
7 Day Performance	-9.93%	-2.01%	-2.17%	-1.39%
1 Month Performance	-47.98%	2.08%	0.54%	-2.63%
1 Year Performance	-54.54%	42.91%	24.66%	8.70%

Ultragenyx Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RARE Ultragenyx Pharmaceutical	2.903 of 5 stars	$13.78 -3.6%	$36.63 +165.8%	-52.8%	$1.36B	$717M	N/A	1,371
COGT Cogent Biosciences	2.151 of 5 stars	$34.76 flat	$51.56 +48.3%	+163.9%	$6.03B	N/A	N/A	80	Positive News
DNTH Dianthus Therapeutics	1.9889 of 5 stars	$108.10 flat	$126.92 +17.4%	+185.8%	$5.91B	$2.04M	N/A	80	Analyst Forecast Gap Up
PTCT PTC Therapeutics	3.8383 of 5 stars	$69.30 flat	$98.55 +42.2%	+8.1%	$5.78B	$1.73B	N/A	1,410	Positive News Analyst Forecast Insider Trade
XENE Xenon Pharmaceuticals	2.2895 of 5 stars	$59.75 flat	$77.13 +29.1%	+62.0%	$5.78B	$7.50M	N/A	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RARE) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. COGT, DNTH, PTCT, XENE, and LGND

How does Ultragenyx Pharmaceutical compare to Cogent Biosciences?

Summary

How does Ultragenyx Pharmaceutical compare to Dianthus Therapeutics?

Summary

How does Ultragenyx Pharmaceutical compare to PTC Therapeutics?

Summary

How does Ultragenyx Pharmaceutical compare to Xenon Pharmaceuticals?

Summary

How does Ultragenyx Pharmaceutical compare to Ligand Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ultragenyx Pharmaceutical (RARE) Competitors

RARE vs. COGT, DNTH, PTCT, XENE, and LGND

How does Ultragenyx Pharmaceutical compare to Cogent Biosciences?

Which has more risk & volatility, COGT or RARE?

Is COGT or RARE more profitable?

Does the media refer more to COGT or RARE?

Do insiders and institutionals have more ownership in COGT or RARE?

Which has preferable valuation and earnings, COGT or RARE?

Do analysts recommend COGT or RARE?

Summary

How does Ultragenyx Pharmaceutical compare to Dianthus Therapeutics?

Do analysts recommend DNTH or RARE?

Do insiders & institutionals hold more shares of DNTH or RARE?

Which has higher earnings & valuation, DNTH or RARE?

Which has more risk and volatility, DNTH or RARE?

Does the media refer more to DNTH or RARE?

Is DNTH or RARE more profitable?

Summary

How does Ultragenyx Pharmaceutical compare to PTC Therapeutics?

Do institutionals and insiders believe in PTCT or RARE?

Do analysts prefer PTCT or RARE?

Does the media refer more to PTCT or RARE?

Which has higher earnings and valuation, PTCT or RARE?

Which has more volatility and risk, PTCT or RARE?

Is PTCT or RARE more profitable?

Summary

How does Ultragenyx Pharmaceutical compare to Xenon Pharmaceuticals?

Does the media refer more to RARE or XENE?

Do insiders & institutionals hold more shares of RARE or XENE?

Which has more risk & volatility, RARE or XENE?

Do analysts rate RARE or XENE?

Is RARE or XENE more profitable?

Which has preferable valuation and earnings, RARE or XENE?

Summary

How does Ultragenyx Pharmaceutical compare to Ligand Pharmaceuticals?

Which has better valuation & earnings, RARE or LGND?

Which has more risk and volatility, RARE or LGND?

Is RARE or LGND more profitable?

Does the media refer more to RARE or LGND?

Do insiders & institutionals believe in RARE or LGND?

Do analysts prefer RARE or LGND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RARE vs. The Competition

Ultragenyx Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools